Dopamine D1/D5 receptor activation modulates a persistent sodium current in rat prefrontal cortical neurons in vitro

J Neurophysiol. 2000 Jul;84(1):75-87. doi: 10.1152/jn.2000.84.1.75.

Abstract

The effects of dopamine (DA) on a persistent Na(+) current (I(NaP)) in layer V-VI prefrontal cortical (PFC) pyramidal cells were studied using whole cell voltage-clamp recordings in rat PFC slices. After blocking K(+) and Ca (2+) currents, a tetrodotoxin-sensitive I(NaP) was activated by slow depolarizing voltage ramps or voltage steps. DA modulated the I(NaP) in a voltage-dependent manner: increased amplitude of I(NaP) at potentials more negative than -40 mV, but decreased at more positive potentials. DA also slowed the inactivation process of I(NaP). The D1/D5 dopamine receptor agonists SKF 38393, SKF 81297, and dihydrexidine (3-10 microM), but not the dopamine D2/D3 receptor agonist qiunpirole (1-20 microM), mimicked the effects of DA on I(NaP). Modulation of I(NaP) by D1/D5 agonists was blocked by the D1/D5 antagonist SCH23390. Bath application of specific protein kinase C inhibitor, chelerhythrine, or inclusion of the specific protein kinase C inhibiting peptide([19-36]) in the recording pipette, but not protein kinase A inhibiting peptide([5-24]), blocked the effect of D1/D5 agonists on I(NaP). In current-clamp recordings, D1/D5 receptors activation enhanced the excitability of cortical pyramidal cells. Application of the D1/D5 agonist SKF 81297 induced a long-lasting decrease in the first spike latency in response to depolarizing current ramp. This was associated with a shift in the start of nonlinearity in the slope resistance to more negative membrane potentials. We proposed that this effect is due to a D1/D5 agonist-induced leftward shift in the activation of I(NaP). This enables DA to facilitate the firing of PFC neurons in response to depolarizing inputs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / pharmacology
  • Alkaloids
  • Animals
  • Benzazepines / pharmacology
  • Benzophenanthridines
  • Cyclic AMP-Dependent Protein Kinases / metabolism
  • Dopamine / pharmacology
  • Dopamine Agonists / pharmacology
  • Enzyme Inhibitors / pharmacology
  • In Vitro Techniques
  • Kinetics
  • Male
  • Membrane Potentials / drug effects
  • Membrane Potentials / physiology
  • Patch-Clamp Techniques
  • Phenanthridines / pharmacology
  • Prefrontal Cortex / cytology*
  • Prefrontal Cortex / physiology
  • Protein Kinase C / antagonists & inhibitors
  • Protein Kinase C / metabolism
  • Pyramidal Cells / chemistry
  • Pyramidal Cells / enzymology*
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Dopamine D1 / physiology*
  • Receptors, Dopamine D5
  • Sodium / metabolism*
  • Tetrodotoxin / pharmacology

Substances

  • Alkaloids
  • Benzazepines
  • Benzophenanthridines
  • Dopamine Agonists
  • Drd5 protein, rat
  • Enzyme Inhibitors
  • Phenanthridines
  • Receptors, Dopamine D1
  • Receptors, Dopamine D5
  • dihydrexidine
  • Tetrodotoxin
  • 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
  • SK&F 81297
  • Sodium
  • chelerythrine
  • Cyclic AMP-Dependent Protein Kinases
  • Protein Kinase C
  • Dopamine